Episode
Kazmira Therapeutics and the Future of CBD Medicine
- Podcast
- Blunt Business
- Published
- Jun 10, 2026
- Duration seconds
- 1704
- Processing state
not_requested- Canonical source
- https://cannabisradio.com/audio/7919
Actions
POST https://stenobird.com/v1/public/podcasts/blunt-business-326858/episodes/kazmira-therapeutics-and-the-future-of-cbd-medicine/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blunt-business-326858/kazmira-therapeutics-and-the-future-of-cbd-medicine.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations. This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy